STOCK TITAN

Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced plans to release its first quarter 2023 financial results on May 9, 2023, accompanied by a conference call at 8:30 A.M. (EST). The conference call will be accessible via live webcast on Perrigo's investor relations website. A taped replay will be available from 12:00 P.M. (EST) on May 9 until midnight on May 16, 2023.

Perrigo focuses on Consumer Self-Care Products and over-the-counter health solutions, aiming to empower consumers in managing their health independently. The company warns that the earnings report may include forward-looking statements, which are subject to various risks and uncertainties.

Positive
  • None.
Negative
  • None.

DUBLIN, April 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023. The Company will also host a conference call beginning at 8:30 A.M. (EST).

The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 1820838. A taped replay of the call will be available beginning at approximately 12:00 P.M. (EST) Tuesday, May 9, until midnight Tuesday, May 16, 2023. To listen to the replay, dial 877-344-7529, International 412-317-0088, and use access code 9673356.

About Perrigo 

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2022.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-first-quarter-2023-financial-results-on-may-9-2023-301806866.html

SOURCE Perrigo Company plc

FAQ

When will Perrigo release its first quarter 2023 financial results?

Perrigo will release its first quarter 2023 financial results on May 9, 2023.

What time is the Perrigo conference call on May 9, 2023?

The Perrigo conference call is scheduled for 8:30 A.M. (EST) on May 9, 2023.

How can I access Perrigo's conference call?

The conference call can be accessed via live webcast on Perrigo's investor relations website.

Is there a replay available for the Perrigo conference call?

Yes, a taped replay of the call will be available from 12:00 P.M. (EST) on May 9 until midnight on May 16, 2023.

What does Perrigo do?

Perrigo is a leading provider of consumer self-care products and over-the-counter health solutions.

PERRIGO COMPANY PLC

NYSE:PRGO

PRGO Rankings

PRGO Latest News

PRGO Stock Data

3.53B
135.94M
0.32%
100.03%
3.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2